Introducing Hot Shots, a series that examines how Ozempic and other GLP-1 drugs have transformed the way we think about our bodies, weight loss, and wellness. Ozempic and other GLP-1 drugs like it ...

The Food and Drug Administration ... a Super Bowl ad touting its weight loss product offerings, markets a compounded version of semaglutide, the active ingredient in Ozempic and Wegovy.

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.

In her last week at AdExchanger, Senior Editor Alyssa Boyle reflects on three years of change, and stasis, in the CTV space.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

A fast-growing body of research signals potential health benefits of GLP-1s, the class of diabetes and weight-loss drugs known by names like Ozempic, beyond what they were initially approved to treat.